JP2011501941A5 - - Google Patents

Download PDF

Info

Publication number
JP2011501941A5
JP2011501941A5 JP2010514184A JP2010514184A JP2011501941A5 JP 2011501941 A5 JP2011501941 A5 JP 2011501941A5 JP 2010514184 A JP2010514184 A JP 2010514184A JP 2010514184 A JP2010514184 A JP 2010514184A JP 2011501941 A5 JP2011501941 A5 JP 2011501941A5
Authority
JP
Japan
Prior art keywords
leucine
amine
acid
alpha
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010514184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011501941A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2008/002490 external-priority patent/WO2009007849A2/en
Publication of JP2011501941A publication Critical patent/JP2011501941A/ja
Publication of JP2011501941A5 publication Critical patent/JP2011501941A5/ja
Withdrawn legal-status Critical Current

Links

JP2010514184A 2007-07-06 2008-07-07 Il−23レセプターのアンタゴニストおよびその使用 Withdrawn JP2011501941A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95866007P 2007-07-06 2007-07-06
PCT/IB2008/002490 WO2009007849A2 (en) 2007-07-06 2008-07-07 Il-23 receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
JP2011501941A JP2011501941A (ja) 2011-01-20
JP2011501941A5 true JP2011501941A5 (cg-RX-API-DMAC7.html) 2011-08-25

Family

ID=40229172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010514184A Withdrawn JP2011501941A (ja) 2007-07-06 2008-07-07 Il−23レセプターのアンタゴニストおよびその使用

Country Status (8)

Country Link
US (1) US20100190710A1 (cg-RX-API-DMAC7.html)
EP (1) EP2288621A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011501941A (cg-RX-API-DMAC7.html)
CN (1) CN101990547A (cg-RX-API-DMAC7.html)
AU (1) AU2008273814A1 (cg-RX-API-DMAC7.html)
CA (1) CA2692037A1 (cg-RX-API-DMAC7.html)
IL (1) IL202752A0 (cg-RX-API-DMAC7.html)
WO (1) WO2009007849A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6077461B2 (ja) 2011-01-04 2017-02-08 ウニヴェルズィテート チューリッヒ アルツハイマー病の予防又は治療のためのil−12及び/又はil−23のモジュレーター
WO2012112319A1 (en) * 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
US9605027B2 (en) * 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
USRE49026E1 (en) * 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
BR112013033617B1 (pt) 2011-06-27 2021-10-26 Galderma Research & Development Uso de mrna, método para o diagnóstico de acne, métodos para o monitoramento da progressão ou variação de acne e da eficácia de um tratamento para tratar acne, e de triagem in vitro para a identificação de inibidores de diferenciação de células th17
EP2723890B1 (en) * 2011-06-27 2019-10-09 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
CZ2012829A3 (cs) * 2012-11-23 2014-06-11 Biotechnologický Ústav Av Čr, V.V.I. Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス, インコーポレイテッド 新規のα4β7ペプチド単量体及び二量体拮抗薬
HK1257747A1 (zh) * 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
WO2018022937A1 (en) * 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN108618100B (zh) * 2018-05-10 2021-07-27 广东天企生物科技有限公司 一种具有鲜味和增鲜特性的四肽及其用途
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
WO2024003313A1 (en) * 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists
WO2026067838A1 (zh) * 2024-09-30 2026-04-02 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061165A1 (en) * 1999-04-13 2000-10-19 Smithkline Beecham Corporation Conserved adhesin motif and methods of use thereof
EP1221482B1 (en) * 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
ATE440864T1 (de) * 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
AU2006264567A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof

Similar Documents

Publication Publication Date Title
Botti et al. Native chemical ligation using removable Nα-(1-phenyl-2-mercaptoethyl) auxiliaries
JP4081501B2 (ja) 新規カッパレセプター選択的オピオイドペプチド
JP2013500990A5 (cg-RX-API-DMAC7.html)
CN101990547A (zh) Il-23受体拮抗剂以及其应用
EP2044102A2 (en) Inhibition of alpha-synuclein aggregation
CA2778236A1 (en) Gadd45beta targeting agents
US20140107031A1 (en) Template-fixed peptidomimetics
Chorev et al. Modifications of position 12 in a parathyroid hormone and parathyroid hormone-related protein: toward the design of highly potent antagonists
US20110262508A1 (en) Antimicrobial compositions, formulations and uses thereof
CN1050721A (zh) 放射性标记的抗凝血多肽
JP5519622B2 (ja) ニューロメジンbおよびソマトスタチンレセプターアゴニスト
JP2007535910A5 (cg-RX-API-DMAC7.html)
JP2020521784A5 (cg-RX-API-DMAC7.html)
CN116888146A (zh) 胰高血糖素样肽-1受体拮抗剂
JP2008517998A5 (cg-RX-API-DMAC7.html)
CN1119650A (zh) 具有胃肠道运动刺激活性的胃动素样多肽
EP4137502A1 (en) Vipr2 antagonist peptide
JP2016505514A5 (cg-RX-API-DMAC7.html)
DeGraw et al. Stabilized analogs of thymopentin. 1. 4, 5-ketomethylene pseudopeptides
Hill et al. Enantioselection in peptide bond formation
CN1039126C (zh) 抗塔基奎宁的三环化合物,及含该化合物的药物组合物
EP1725580B1 (en) Isosteric transformation
JP7218906B2 (ja) 血管機能の検出方法、高血圧症の進行段階を判定する方法、高血圧症の進行段階を判定するためのキット及び高血圧症の治療効果の予測方法
JP2014515751A (ja) 成長ホルモン放出因子(grf)類似体およびその使用
Samant et al. Norcystine, a new tool for the study of the structure− activity relationship of peptides